Earnings summaries and quarterly performance for Spero Therapeutics.
Executive leadership at Spero Therapeutics.
Board of directors at Spero Therapeutics.
Research analysts who have asked questions during Spero Therapeutics earnings calls.
RB
Ritu Baral
TD Cowen
2 questions for SPRO
Also covers: ACAD, ALNY, ATAI +11 more
Gautam Chukka
Evercore ISI
1 question for SPRO
Gavin Clark-Gartner
Evercore ISI
1 question for SPRO
Also covers: ACRS, ARGX, ASND +11 more
LC
Louise Chen
Cantor Fitzgerald
1 question for SPRO
Also covers: ARDX, CNTB, IMAB +14 more
RS
Ram Selvaraju
H.C. Wainwright
1 question for SPRO
Also covers: ABEO, ADXN, BCPC +8 more
Recent press releases and 8-K filings for SPRO.
Spero Therapeutics' Partner GSK Resubmits NDA for Tebipenem HBr
SPRO
Product Launch
New Projects/Investments
- Spero Therapeutics' development partner, GSK, has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic for complicated urinary tract infections (cUTI), including pyelonephritis.
- The NDA resubmission is supported by results from the successful Phase 3 PIVOT-PO trial, which was stopped early for efficacy in May 2025 following a planned interim analysis.
- This resubmission triggers a $25 million milestone payment to Spero, which is expected to be received in Q1 2026.
Dec 19, 2025, 1:00 PM
Spero Therapeutics Announces Q3 2025 Results and Tebipenem HBr FDA Filing Plans
SPRO
Earnings
Guidance Update
New Projects/Investments
- Spero Therapeutics reported a net loss of $7.4 million and total revenue of $5.4 million for the third quarter ended September 30, 2025.
- The company's development partner, GSK, plans to submit data from the Phase 3 PIVOT-PO trial for tebipenem HBr to the US FDA in Q4 2025, with a regulatory decision anticipated in 2H 2026. The trial demonstrated non-inferiority of tebipenem HBr compared to intravenous imipenem-cilastatin for complicated urinary tract infection (cUTI), with an overall success rate of 58.5%.
- Spero Therapeutics has discontinued the SPR720 program in Q3 2025 following a review of Phase 2a and Phase 1 trial data.
- As of September 30, 2025, Spero had $48.6 million in cash and cash equivalents, which is expected to fund operations into 2028.
Nov 13, 2025, 10:18 PM
Spyre Therapeutics Announces Closing of Public Offering
SPRO
New Projects/Investments
- Spyre Therapeutics, Inc. announced the closing of its underwritten public offering, which included the full exercise of the underwriters’ option to purchase additional shares.
- The offering comprised 17,094,594 shares of common stock at a public offering price of $18.50 per share.
- The gross proceeds generated from the offering totaled approximately $316.2 million.
Oct 15, 2025, 8:15 PM
Spero Therapeutics Updates on Tebipenem Phase III Progress and GSK Partnership
SPRO
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Spero Therapeutics' lead asset, tebipenem (tebi HBr), a potential first oral carbapenem for complicated urinary tract infections (cUTI), has completed over 60% enrollment in its Phase III trial, with full enrollment anticipated in the second half of 2025.
- The company's cash runway extends into mid-2026.
- Spero has received $200 million in funding from GSK for tebi HBr, with potential for up to $400 million in additional regulatory and commercial milestones and tiered royalties.
- An additional $47.5 million in committed milestones from GSK remains, and a $25 million contingent milestone is expected upon GSK's NDA submission, guided for the end of 2025.
- The wholly-owned asset SPR-720 for non-refractory NTM-PD showed activity but dose-limiting toxicities in a Phase IIa trial; next steps will be determined later in 2025 after full data analysis.
Mar 4, 2025, 8:10 PM
Spero Therapeutics Updates on Tebi HBr Phase III Progress and Pipeline
SPRO
New Projects/Investments
Guidance Update
Revenue Acceleration/Inflection
- Spero Therapeutics' lead asset, Tebi HBr, an oral carbapenem for complicated urinary tract infections (cUTI), is in a Phase III trial with over 60% enrollment completed in 2024, and full enrollment is guided for the second half of this year.
- The company has a financial runway into mid-2026 and has received $200 million in funding from its partnership with GSK for Tebi HBr, with potential for up to $400 million in additional regulatory and commercial milestones.
- Spero expects to receive $47.5 million in remaining committed milestones for Tebi HBr's Phase III development, and a $25 million contingent milestone upon GSK's NDA submission, which is guided for the end of this year.
- The SPR-720 program for NTM-PD patients, a wholly owned asset, has suspended its oral program due to dose-limiting toxicities despite showing activity, and the company is exploring potential inhaled formulations.
Mar 4, 2025, 8:10 PM
Quarterly earnings call transcripts for Spero Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more